73 results about "Dextran sodium sulfate" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of extracellular vesicle-like particles derived from divaricate saposhnikovia roots in preparation of medicines for preventing and treating intestinal diseases. Research on the physiological efficacy of the extracellular vesicle-like particles from divaricate saposhnikovia root shows that the extracellular vesicle-like particles can relieve colon shortening and colon tissue damage caused by dextran sodium sulfate, relieve intestinal inflammation and promote repair of intestinal barriers including mechanical barriers, chemical barriers and immune barriers. The polypeptide has potential for preparing the medicine for treating the intestinal diseases, and a new strategy is provided for preventing or treating the intestinal diseases.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention discloses a construction method and application of a probiotic engineering bacterium EcNpAm targeting animal intestinal tracts and improving inflammation. According to the present invention, the heterologous expression of the immunomodulatory protein Amuc1100 is successfully achieved through the gene engineering technology by using the Escherichia coli Niss1917 (EcN) as the host and using the anaerobic inducible plasmid pnirBMisL as the expression vector, and the novel engineering bacterium EcNpAm suitable for the animal intestinal anaerobic environment is constructed; furthermore, the expression efficiency of the target protein is represented by fusion expression of green fluorescent protein (GFP). The engineering bacterium is applied to prevention and treatment of animal intestinal inflammation, and successfully realizes targeted delivery of therapeutic protein to intestinal tracts of mice. Experiments show that EcNpAm can effectively relieve typical symptoms such as weight loss, colon shortening, pathological injury, colitis and the like of mice induced by dextran sodium sulfate (DSS) and protect integrity and functions of an intestinal barrier structure.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention discloses an application of a bee sugar plum seed alcohol extract in preparation of an anti-colitis medicine. The invention finds that the bee sugar plum seed alcohol extract inhibits the generation of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) under the condition of no cytotoxicity; the bee sugar plum seed alcohol extract inhibits transcription of LPS-induced pro-inflammatory cytokine genes and expression of genes and proteins of synthetic pro-inflammatory mediator enzymes (iNOS and COX-2); the bee sugar plum seed alcohol extract not only inhibits nuclear transfer of NF-kappa B by reducing phosphorylation and degradation of I kappa B alpha, but also inhibits phosphorylation of MPAKs (ERK, p38 and JNK); the traditional Chinese medicine composition has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis. Therefore, the bee sugar plum seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The invention relates to the field of biological medicine, in particular to polypeptide for inhibiting TBK1 and inflammation and application. The invention provides a series of polypeptides. A cell-penetrating peptide sequence TAT capable of penetrating a cell membrane and a connecting sequence (GSG) are added to the N end of the amino acid sequence of the polypeptides. The sequence can target TBK1 and influence the interaction of TBK1-STING-IRF3 so as to influence the activation of a pathway and achieve the purpose of inhibiting inflammation. The TBK1 targeting peptide LK shows remarkable anti-inflammatory activity in various established mouse inflammation or autoimmune disease models, including a lipopolysaccharide (LPS) induced systemic and acute inflammation model, a dextran sodium sulfate (DSS) induced ulcerative colitis model and a Trex1 defect AGS model. In addition, the polypeptide LK shows even a strong synergistic effect with a PD-1 antibody in cancer immunotherapy in various in vivo tumor models.

The invention discloses a chitosan non-binding bilirubin microsphere as well as a preparation method and application thereof. The chitosan non-binding bilirubin microspheres are prepared by taking chitosan as a delivery carrier and taking chitosan and bilirubin as main raw materials through an emulsion reaction and a cross-linking reaction in sequence. Chitosan (CIS) is selected as a carrier for delivering unbound bilirubin (UCB), and the chitosan unbound bilirubin microspheres are prepared through an emulsion reaction and a cross-linking reaction, so that the UCB is more safely and efficiently fed into the intestinal tract to reach an inflammation part, and experiments prove that the UCB can be used for preparing the unbound bilirubin microspheres. The chitosan non-binding bilirubin microsphere has a remarkable protective effect on the intestinal immune function, microbiota disorder and barrier function of a dextran sodium sulfate (DSS) induced ulcerative colitis (UC) mouse.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The invention discloses polygonum multiflorum polysaccharide, a preparation method and application of the polygonum multiflorum polysaccharide in preparation of a medicine for treating ulcerative colitis. Polygonum multiflorum polysaccharide is obtained through extraction, deproteinization and column chromatography of Polygonum multiflorum. By establishing a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse model to evaluate the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide, it is proved that the polygonum multiflorum polysaccharide has the advantages that the weight of the ulcerative colitis model mouse is remarkably increased, the hemafecia index and the loose stool index are remarkably reduced, the colon length is increased, and the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide is remarkably improved. The richness of intestinal flora is effectively improved, the pathological damage of the colonic tissue of an ulcerative colitis model mouse is effectively improved, and the purpose of treating ulcerative colitis is achieved. Therefore, it is proved for the first time that the polygonum multiflorum polysaccharide has a remarkable ulcerative colitis resisting effect, and an important theoretical basis is provided for development of ulcerative colitis resisting drugs.

The invention discloses an application of a prunus tomentosa seed alcohol extract in preparation of an anti-colitis medicine. In the invention, the prunus tomentosa seed alcohol extract with the function of resisting colitis is obtained by reflux extraction of prunus tomentosa seeds with 70% ethanol, and has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis; wherein the weight loss of the mouse is slowed down, the DAI score of the mouse is reduced, the injury of the colon tissue of the mouse is relieved, the content of IL-6, IL-1beta, TNF-alpha and MDA in the colon tissue and serum of the mouse is reduced, and the activity of CAT and SOD in the colon tissue and serum of the mouse is enhanced. The prunus tomentosa seed alcohol extract inhibits the activation of ROS-mediated MAPKs and NF-kappa B pathways, and further inhibits the excessive secretion of proinflammatory mediators NO and PGE2 and proinflammatory cytokines TNF-alpha, IL-6 and IL-1beta in lipopolysaccharide-induced RAW264.7 cells. Therefore, the prunus tomentosa seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The present application discloses isoschaftoside and its compositions and uses. Experiments have proven that isoschaftoside can significantly improve dextran sulfate sodium-induced colitis in mice, specifically manifested as significantly alleviating the weight loss and shortening of colon length caused by the model establishment; significantly reducing the disease activity index and spleen weight of mice; significantly alleviating the pathological changes in the colon tissues of mice, including reducing inflammatory cell infiltration, restoring the crypt structure of the tissue and the number of intestinal glands, and having significant anti-ulcerative colitis activity, showing good application prospects in the preparation of drugs for treating ulcerative colitis.

The invention discloses a colon-targeted Pickering emulsion stabilized by rhein-chitosan composite nanoparticles, a preparation method and an application of the colon-targeted Pickering emulsion. Rhein-chitosan is coupled and then crosslinked with sodium tripolyphosphate to form the rhein-chitosan composite nano-particles, and the nano-particles have better hydrophobicity and acid and alkali resistance stability; the nano-particle suspension and fish oil containing rhein are homogenized and emulsified at a high speed to obtain the Pickering emulsion entrapped with the rhein, and the Pickering emulsion has relatively high rhein drug loading capacity, better stability and good colon-specific release and slow release characteristics; and the traditional Chinese medicine composition has a dose-dependent relieving effect on dextran sodium sulfate induced ulcerative colitis mice, can inhibit inflammatory response and repair intestinal barrier functions, can effectively avoid intestinal nutrition loss caused by rhein, and has a good application prospect.

The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LTα, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LTα− / − Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LTα expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

The invention provides application of a five-membered heterocycle substituted styrene derivative in preparation of a medicine for treating ulcerative colitis and / or improving intestinal barrier function and the medicine. The five-membered heterocycle substituted styrene derivative disclosed by the invention not only can be used for remarkably relieving symptoms of mouse ulcerative colitis (UC) induced by dextran sodium sulfate (DSS), but also is safe and free from toxic and side effects. The invention also verifies that the five-membered heterocycle substituted styrene derivative has an anti-inflammatory effect, can improve the barrier function of the intestinal tract, and can inhibit the increase of the permeability of the intestinal tract caused by ulcerative colitis. According to the application, the treatment effect of the five-membered heterocycle substituted styrene derivative on ulcerative colitis and the improvement effect on the intestinal barrier function are defined from the action mechanism, and the activation of an aromatic receptor can also improve the intestinal immune function; the invention provides a new therapeutic target and theoretical basis for fundamental research and clinical treatment of ulcerative colitis.

The present invention relates to a sanguisorba officinalis polysaccharide, its preparation method and uses. In the sanguisorba officinalis polysaccharide of the present invention, by weight percentage, the neutral sugar content is 79% - 85%, the uronic acid content is 13% - 19%, and the protein content is 1% - 4%. The composition of the polysaccharide includes mannose, rhamnose, galacturonic acid, galactose, xylose and arabinose. In vitro and in vivo experiments have proved that the sanguisorba officinalis polysaccharide can significantly inhibit the expression of inflammation-related factors in the enteritis cell model and relieve the symptoms of dextran sulfate sodium-induced acute colitis in mice, including the weight loss of mice, the increase of spleen weight index, the reduction of colon length and the intestinal structure damage. And it has no effect on the growth viability of normal intestinal epithelial cells in vitro and has no toxic effect on the important organs of mice in vivo, with high safety. Therefore, the polysaccharide has the potential to treat gastrointestinal inflammatory diseases and is expected to become a candidate carbohydrate drug for treating gastrointestinal inflammatory diseases.

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

The invention relates to a probiotic composition and application thereof, and belongs to the technical field of compositions. Comprising Ackerman muciniphila ATCC BAA-835 and Bifidobacterium animalis subsp. Lactis BB-12, wherein the CFU (colony forming unit) ratio of the Ackerman muciniphila ATCC BAA-835 to the Bifidobacterium animalis subsp. Lactis BB-12 is 1 The two strains have a synergistic effect, and the prepared probiotic composition can synergistically relieve the phenomena of weight loss, colon shortening, intestinal structure and intestinal barrier injury, proinflammatory factor increase, anti-inflammatory factor reduction, intestinal flora and histidine metabolism disorder and the like of dextran sodium sulfate induced mouse ulcerative colitis. Therefore, the effect of preventing and relieving the severity of the inflammatory bowel disease is achieved.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The invention provides a preparation method of sodium dextran sulfate and application of the sodium dextran sulfate in red fading cosmetics, and relates to the technical field of catalytic synthesis. The preparation method comprises the following steps: S1, mixing glucan with the molecular weight of 1.5-30 thousand, beta-glucanase and a ZSM-5 molecular sieve to obtain pretreated glucan; s2, the pretreated dextran, a sulfonating reagent and a catalyst are mixed for a reaction, and dextran sulfate is obtained; s3, enabling the dextran sulfate to react with sodium salt, so as to obtain the dextran sulfate sodium. According to the specific preparation method disclosed by the invention, high-purity dextran sodium sulfate with specific molecular weight is obtained through specific raw materials, reaction conditions, refining steps, refining solvents and the like, and the stability is improved.

The invention relates to a water-based binder for a positive electrode of a lithium ion battery, a preparation method and application. The preparation method comprises the following steps: dissolving dextran sodium sulfate (DSS) in deionized water, adding a crosslinking reinforcing agent, and stirring and crosslinking at normal temperature to obtain the water-based adhesive. The aqueous binder can form a flexible and firm three-dimensional network structure on the whole positive electrode slurry, and the network structure can maintain the integrity of an electrode, effectively improve the first coulombic efficiency of a battery, inhibit voltage attenuation, enhance the conductivity of a positive electrode, accelerate reaction kinetics, optimize a transmission path and improve the stability of the battery. The charge-discharge cycle stability, the rate capability and the like of the battery are greatly improved, and the battery with stable capacity and long cycle life is obtained; within the voltage of 2-4.8 V, the 0.1 C first-circle discharge specific capacity can reach 296.7 mAh / g or above, the first efficiency is improved to 85.72% or above, and the capacity retention ratio after 300 cycles under the current of 1 C is 99.31% and 93.70% after 400 cycles. The preparation process is simple and environment-friendly, low in equipment requirement and low in energy consumption.

The invention relates to the technical field of microorganisms, and particularly discloses a strain Kazachstaniapintoolipesii as well as screening, culture and application of the strain Kazachstaniapintoolipesii. The bacterial strain is obtained through mouse excrement screening, morphological observation and 18S rRNA sequencing identification and can effectively improve mouse inflammatory enteritis induced by dextran sodium sulfate (DSS), and the inflammatory enteritis is represented as weight recovery, intestinal length increase, serum inflammatory cytokine (IL-1beta and IL-6) level reduction, intestinal flora balance regulation and intestinal inflammation relieving. The strain can be used for preparing medicines, pharmaceutical compositions, foods, health-care products or food additives for preventing and / or treating inflammatory enteritis, and has remarkable application value.

Provided is a method for preventing and alleviating inflammatory bowel disease by administering a composition including puer tea extract as an active ingredient to a subject in need thereof. Puer tea extract of the present disclosure showed an effect of improving damaged colonic tissue in a mouse model of acute ulcerative colitis induced by dextran sulfate sodium (DSS), and showed an inhibitory effect on clinical symptoms of the disease activity index (DAT) of weight loss, diarrhea, and rectal bleeding. In addition, puer tea extract inhibited the expression of inflammatory cytokines TNF-α and IL-6 in the colonic tissue and inhibited the inflammatory response through inhibition of the activity of NF-κB, an anti-inflammatory mechanism. In addition, the DPPH free radical and ABTS free radical scavenging ability increased proportionally as the concentration of puer tea extract increased at the cellular level, and COX-2 expression was inhibited in LPS-activated macrophages.